Pancreatic Cancer Research

ResearcherLeiden University Medical CenterActive in the last 2 years

Gijs A. Patijn

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8113-4171; OpenAlex author ID A5005932214, A5043134557, A5077541746. Sources: OpenAlex.

Their work

Papers
42 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
111
Papers, trials and grants by year

2016: 2 papers · 2017: 1 paper · 2018: none · 2019: none · 2020: 3 papers · 2021: 6 papers · 2022: 2 papers · 2023: 7 papers · 2024: 8 papers · 2025: 7 papers · 2026: 6 papers

Papers 42

  1. Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. Co-author DOI 10.1001/jamanetworkopen.2026.3861↗
  2. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  3. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  4. Gastrointestinal symptoms and health-related quality of life before and after pancreatectomy for pancreatic cancer (GO-PANC): longitudinal nationwide study. Co-author DOI 10.1093/bjs/znag122↗
  5. Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial. Co-author DOI 10.1097/sla.0000000000007025↗
  6. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  7. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  8. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  9. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  10. Evaluation of Short and Long-term Outcomes After Resection in Patients With Locally Advanced Versus (Borderline) Resectable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006289↗
  11. Perineural Invasion is an Important Prognostic Factor in Patients With Radically Resected (R0) and Node-negative (pN0) Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006320↗
  12. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  13. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  14. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  15. Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancrea… Co-author DOI 10.1016/j.surg.2024.01.029↗
  16. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Co-author DOI 10.1093/jnci/djae070↗
  17. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study. Co-author DOI 10.1097/sla.0000000000006021↗
  18. Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort Study. Co-author DOI 10.1097/sla.0000000000006539↗
  19. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  20. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  21. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis. Co-author DOI 10.1245/s10434-024-15070-w↗
  22. The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial. Co-author DOI 10.1016/j.ejso.2022.12.011↗
  23. Nationwide evaluation of pancreatic cancer networks ten years after the centralization of pancreatic surgery. Co-author DOI 10.1016/j.hpb.2023.07.904↗
  24. Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable pancreatic cancer. Last author DOI 10.1016/j.suronc.2023.101909↗
  25. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderl… Co-author DOI 10.1093/bjs/znad210↗
  26. Impact of complications after resection of pancreatic cancer on disease recurrence and survival, and mediation effect of adjuvant chemotherapy: nationwide, obs… Co-author DOI 10.1093/bjsopen/zrac174↗
  27. Outcome of Pancreatic Surgery During the First 6 Years of a Mandatory Audit Within the Dutch Pancreatic Cancer Group. Co-author DOI 10.1097/sla.0000000000005628↗
  28. Early Recurrence After Resection of Locally Advanced Pancreatic Cancer Following Induction Therapy: An International Multicenter Study. Co-author DOI 10.1097/sla.0000000000005666↗
  29. Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderl… Co-author DOI 10.1097/sla.0000000000004313↗
  30. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREO… Co-author DOI 10.1200/jco.21.02233↗
  31. Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of t… Co-author DOI 10.1002/jso.26567↗
  32. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. Co-author DOI 10.1016/j.ejso.2020.11.137↗
  33. The treatment and survival of elderly patients with locally advanced pancreatic cancer: A post-hoc analysis of a multicenter registry. Co-author DOI 10.1016/j.pan.2020.11.012↗
  34. Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only: Multicenter Propensity Score-… Co-author DOI 10.1097/sla.0000000000005120↗
  35. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreati… Co-author DOI 10.1186/s12885-021-08031-z↗
  36. Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled… Co-author DOI 10.1186/s13063-021-05248-y↗
  37. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled t… Co-author DOI 10.1186/s13063-020-4180-z↗
  38. The ultimate preoperative C-reactive protein-to-albumin ratio is a prognostic factor for survival after pancreatic cancer resection. Co-author DOI 10.1186/s40001-020-00444-z↗
  39. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III P… Co-author DOI 10.1200/jco.19.02274↗
  40. Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. Co-author DOI 10.1016/j.hpb.2017.06.010↗
  41. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multi… Co-author DOI 10.1186/s13063-016-1262-z↗
  42. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis. Co-author DOI 10.1245/s10434-015-4930-4↗

Closest collaborators

The 25 strongest of 111 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 30 shared papers, 2016–2026 · strength 3.87
  2. Ignace H. J. T. de Hingh · 29 shared papers, 2016–2026 · strength 3.67
  3. Hjalmar C. van Santvoort · 23 shared papers, 2016–2026 · strength 3.09
  4. Sebastiaan Festen · 22 shared papers, 2016–2026 · strength 2.88
  5. Bas Groot Koerkamp · 21 shared papers, 2017–2026 · strength 2.87
  6. Casper H.J. van Eijck · 22 shared papers, 2016–2026 · strength 2.83
  7. Martijn W.J. Stommel · 18 shared papers, 2021–2026 · strength 2.54
  8. Izaak Quintus Molenaar · 20 shared papers, 2016–2026 · strength 2.42
  9. Bert A. Bonsing · 17 shared papers, 2016–2026 · strength 2.07
  10. Vincent Erwin de Meijer · 15 shared papers, 2021–2026 · strength 2.01
  11. Lois A. Daamen · 12 shared papers, 2021–2026 · strength 1.82
  12. Johanna W. Wilmink · 13 shared papers, 2020–2026 · strength 1.64
  13. Geertjan van Tienhoven · 13 shared papers, 2016–2026 · strength 1.61
  14. J. Sven D. Mieog · 9 shared papers, 2022–2026 · strength 1.41
  15. Geert Kazemier M · 10 shared papers, 2016–2026 · strength 1.35
  16. Judith de Vos‐Geelen · 12 shared papers, 2016–2025 · strength 1.30
  17. Thijs J. Schouten · 7 shared papers, 2021–2026 · strength 1.09
  18. Thomas F. Stoop · 6 shared papers, 2024–2026 · strength 1.02
  19. Marion B.M. van der Kolk · 7 shared papers, 2016–2026 · strength 0.96
  20. Marjolein Y.V. Homs · 7 shared papers, 2020–2026 · strength 0.95
  21. Marieke S. Walma · 8 shared papers, 2021–2025 · strength 0.93
  22. Lilly J. H. Brada · 8 shared papers, 2021–2025 · strength 0.93
  23. Jacob L. van Dam · 6 shared papers, 2021–2026 · strength 0.87
  24. Freek D. Daams · 6 shared papers, 2021–2026 · strength 0.79
  25. Eva Versteijne · 7 shared papers, 2016–2025 · strength 0.77

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.